Can you take Cyclophosphamide with Focinvez?

cycloPHOSphamide has a major potential interaction with Bladder Infection.

The use of cyclophosphamide is contraindicated in patients with urinary outflow obstruction. Urinary tract obstruction should be excluded or corrected before treatment because cyclophosphamide can cause urotoxicity, which may be fatal.

cycloPHOSphamide has a major potential interaction with Bleeding Disorder.

Cyclophosphamide should not be administered to patients with neutrophil counts of 1,500/mm3 or less and platelet counts below 50,000/mm3. Cyclophosphamide can cause myelosuppression, bone marrow failure, and severe immunosuppression; complete blood counts should be monitored during treatment.

cycloPHOSphamide has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Cyclophosphamide should not be administered to patients with neutrophil counts of 1,500/mm3 or less and platelet counts below 50,000/mm3. Cyclophosphamide can cause myelosuppression, bone marrow failure, and severe immunosuppression; complete blood counts should be monitored during treatment.

cycloPHOSphamide has a moderate potential interaction with Fever.

Cyclophosphamide treatment may not be indicated, or may require interruption or dose reduction, in patients with a serious infection. Cyclophosphamide can cause severe immunosuppression and reactivate latent infections; it should be used with caution, if at all, in patients with active urinary tract infections.

cycloPHOSphamide has a moderate potential interaction with Heart Disease.

Cyclophosphamide can cause myocarditis, myopericarditis, pericardial effusion, arrhythmias, and congestive heart failure, which may be fatal. Particular caution is necessary in patients with pre-existing cardiac disease; monitor these patients for cardiotoxicity.

cycloPHOSphamide has a moderate potential interaction with History, Radiation Therapy.

Previous radiation treatment to the cardiac region may increase the risk of cyclophosphamide cardiotoxicity, and previous abdominal radiation is a risk factor for cyclophosphamide-associated veno-occlusive liver disease. Patients with risk factors for cardiotoxicity should be monitored during treatment.

cycloPHOSphamide has a moderate potential interaction with Infection.

Cyclophosphamide treatment may not be indicated, or may require interruption or dose reduction, in patients with a serious infection. Cyclophosphamide can cause severe immunosuppression and reactivate latent infections; it should be used with caution, if at all, in patients with active urinary tract infections.

cycloPHOSphamide has a moderate potential interaction with Liver Disease.

Pre-existing disturbances of hepatic function are a risk factor for cyclophosphamide-associated veno-occlusive liver disease, which can be fatal. Severe hepatic impairment may reduce conversion of cyclophosphamide to its active metabolite, potentially reducing efficacy.

The fosaprepitant in Focinvez has a moderate potential interaction with Liver Disease.

There are no clinical or pharmacokinetic data in patients with severe liver dysfunction (Child-Pugh score greater than 9); therefore, caution and additional monitoring for adverse reactions are recommended when using fosaprepitant in these patients.

cycloPHOSphamide has a moderate potential interaction with Pulmonary Impairment.

Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide. Pneumonitis may develop years after treatment with cyclophosphamide. Patients should be monitored for signs and symptoms of pulmonary toxicity. Caution is advised in patients with preexisting pulmonary impairment.

cycloPHOSphamide has a moderate potential interaction with Renal Dysfunction.

In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may result in increased toxicity. Monitor patients with severe renal impairment (CrCl =10 mL/min to 24 mL/min) for signs and symptoms of toxicity. Therapy with cyclophosphamide should be administered cautiously in patients with a history of or predisposition to renal dysfunction. Clinical monitoring of renal function is recommended.

cycloPHOSphamide has a major potential interaction with Urinary Tract Infection.

The use of cyclophosphamide is contraindicated in patients with urinary outflow obstruction. Urinary tract obstruction should be excluded or corrected before treatment because cyclophosphamide can cause urotoxicity, which may be fatal.

cycloPHOSphamide has a major potential interaction with Urinary Tract Obstruction.

The use of cyclophosphamide is contraindicated in patients with urinary outflow obstruction. Urinary tract obstruction should be excluded or corrected before treatment because cyclophosphamide can cause urotoxicity, which may be fatal.